Luye Pharma Group Ltd.
Luye Pharma Group Ltd.
Explore linked clinical trials.14 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mass Balance Study of [14C] LPM3770164 in Healthy Participants | Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Huntington disease, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, hereditary disease, inherited neurodegenerative disorder, movement disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder | Not yet recruiting | Phase 1 | 2026-04-08 | NCT07516899 | |
| A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Not yet recruiting | Phase 2 | 2026-02-09 | NCT07396870 | |
| LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-02-06 | NCT07391566 | |
| To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 1 | 2026-01-27 | NCT07371065 | |
| A Food Effect Study of LY03020 in Healthy Subjects | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Active, not recruiting | Phase 1 | 2025-12-18 | NCT07292233 | |
| Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) | Assisted Reproduction | Active, not recruiting | Phase 2 | 2025-11-19 | NCT07236476 | |
| A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 1 | 2025-11-19 | NCT07230652 | |
| A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 | Hallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disorders | Not yet recruiting | Phase 1 | 2025-05-20 | NCT06980207 | |
| Effect of Food and Age on the Pharmacokinetics of LY03017 | Alzheimer's Disease Psychosis; Negative Symptoms of Schizophrenia; Parkinson Disease Psychosis | Not yet recruiting | Phase 1 | 2025-01-27 | NCT06793995 | |
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, tardive dyskinesia | Recruiting | Phase 1 / Phase 2 | 2025-01-22 | NCT06731868 | |
| Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2024-12-12 | NCT06496048 | |
| To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Not yet recruiting | Phase 4 | 2024-05-23 | NCT06426485 | |
| First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. | Advanced Solid Tumor | Recruiting | Phase 1 | 2024-03-15 | NCT06240546 | |
| Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2024-03-15 | NCT06128837 |